2 ms·
So unlike 23andme, (1) realtime COVID diagnosis is extremely timely and actionable to recipients and has a real impact on disease spread, (2) the SCAN tests are
by loeg 7y ago
So unlike 23andme, (1) realtime COVID diagnosis is extremely timely and actionable to recipients and has a real impact on disease spread, (2) the SCAN tests are reliable, targeted, and they have the data to support that, and (3) a positive or negative COVID test seems unlikely to induce suicide, or I don't know, a murder spree. So I don't think this comparison is especially suitable.
In addition, the informed consent form for participants has included language that results might be shared since early March: https://pastebin.com/wj6fMnrw https://pastebin.com/wj6fMnrw So the FDA, in May, claiming to think the study was only surveillance suggests to me a remarkable failing of comprehension by the FDA.
> The FDA has not raised any concerns regarding the safety and accuracy of SCAN’s test
> We have been in conversation with the FDA since March 1st and hope to have our EUA soon. We initiated the process to authorize our lab-developed test and self-swab kit on March 23rd and, in accordance with the EUA process and timeline, submitted data to secure federal authorization on April 13th. We are actively working to address their questions and resume testing as soon as possible.
> We have performed internal studies to determine shipping and specimen stability with our assay, testing approximately 17,000 home-collected mid-turbinate swabs from both adults and children—including Seattle Flu Study and SCAN samples. We have provided the following information to the FDA:
> To date, only a single, minor adverse event has been reported.
> Our shipping and stability studies have established that detection of SARS-CoV-2 is stable for over a week at high and low regional temperatures.
> With regard to proper specimen collection outside of a clinical setting, our experience from more than 18 months of sampling with the Seattle Flu Study and now SCAN also shows a low rate of insufficient nasal sampling. The internal control in our assay readily identifies whether a sufficient specimen is collected.
> Numerous scientific studies have established similar rates of detection for mid-turbinate swabs and the nasal pharyngeal swabs typically used in clinical testing, including for SARS-CoV-2 detection. The Infectious Diseases Society of America (IDSA) guidelines endorse the use of mid-turbinate swabs and reference the potential for self-collection with appropriate instructions.
https://scanpublichealth.org/updates/2020-05-13 https://scanpublichealth.org/updates/2020-05-13